Follow
Enrique M. Ocio
Enrique M. Ocio
Hospital Universitario Marqués de Valdecilla
Verified email at unican.es
Title
Cited by
Cited by
Year
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a …
JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ...
The lancet oncology 15 (11), 1195-1206, 2014
8872014
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a …
M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ...
The Lancet 394 (10214), 2096-2107, 2019
610*2019
International prognostic scoring system for Waldenström macroglobulinemia
P Morel, A Duhamel, P Gobbi, MA Dimopoulos, MV Dhodapkar, J McCoy, ...
Blood, The Journal of the American Society of Hematology 113 (18), 4163-4170, 2009
4502009
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
4242016
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ...
The lancet oncology 20 (6), e302-e312, 2019
3682019
The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes
S Tabera, JA Pérez-Simón, M Díez-Campelo, LI Sánchez-Abarca, ...
haematologica 93 (9), 1301-1309, 2008
3682008
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ...
Leukemia 31 (11), 2443-2448, 2017
3162017
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
P Maiso, X Carvajal-Vergara, EM Ocio, R López-Pérez, G Mateo, ...
Cancer research 66 (11), 5781-5789, 2006
3042006
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, ...
Leukemia 28 (3), 525-542, 2014
3002014
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia
C Jiménez, E Sebastián, MC Chillón, P Giraldo, J Mariano Hernández, ...
Leukemia 27 (8), 1722-1728, 2013
3002013
Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop
RG Owen, RA Kyle, MJ Stone, AC Rawstron, V Leblond, G Merlini, ...
British journal of haematology 160 (2), 171-176, 2013
2902013
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia
MA Dimopoulos, MA Gertz, E Kastritis, R Garcia-Sanz, EK Kimby, ...
J Clin Oncol 27 (1), 120-126, 2009
2542009
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
J Caers, B Paiva, E Zamagni, X Leleu, J Bladé, SY Kristinsson, ...
Journal of hematology & oncology 11, 1-10, 2018
2522018
Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic …
NC Gutierrez, EM Ocio, J de Las Rivas, P Maiso, M Delgado, E Ferminan, ...
Leukemia 21 (3), 541-549, 2007
2212007
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, ...
The Lancet Haematology 6 (9), e459-e469, 2019
2172019
Immunophenotypic analysis of Waldenstrom's macroglobulinemia
JF San Miguel, MB Vidriales, E Ocio, G Mateo, F Sanchez-Guijo, ...
Seminars in oncology 30 (2), 187-195, 2003
2102003
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B Paiva, A Azpilikueta, N Puig, EM Ocio, R Sharma, BO Oyajobi, ...
Leukemia 29 (10), 2110-2113, 2015
1992015
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and …
T Kiziltepe, T Hideshima, L Catley, N Raje, H Yasui, N Shiraishi, Y Okawa, ...
Molecular cancer therapeutics 6 (6), 1718-1727, 2007
1992007
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
SP Treon, MA Gertz, M Dimopoulos, A Anagnostopoulos, J Blade, ...
Blood 107 (9), 3442-3446, 2006
1962006
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ...
The Lancet Oncology 22 (3), e105-e118, 2021
1862021
The system can't perform the operation now. Try again later.
Articles 1–20